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Abstract
Background: Current evidence suggests that endothelial progenitor cells (EPC) contribute to ischemic tissue repair by both
secretion of paracrine factors and incorporation into developing vessels. We tested the hypothesis that cell-free
administration of paracrine factors secreted by cultured EPC may achieve an angiogenic effect equivalent to cell therapy.
Methodology/Principal Findings: EPC-derived conditioned medium (EPC-CM) was obtained from culture expanded EPC
subjected to 72 hours of hypoxia. In vitro, EPC-CM significantly inhibited apoptosis of mature endothelial cells and
promoted angiogenesis in a rat aortic ring assay. The therapeutic potential of EPC-CM as compared to EPC transplantation
was evaluated in a rat model of chronic hindlimb ischemia. Serial intramuscular injections of EPC-CM and EPC both
significantly increased hindlimb blood flow assessed by laser Doppler (81.262.9% and 83.763.0% vs. 53.562.4% of normal,
P,0.01) and improved muscle performance. A significantly increased capillary density (1.6260.03 and 1.6860.05/muscle
fiber, P,0.05), enhanced vascular maturation (8.660.3 and 8.160.4/HPF, P,0.05) and muscle viability corroborated the
findings of improved hindlimb perfusion and muscle function. Furthermore, EPC-CM transplantation stimulated the
mobilization of bone marrow (BM)-derived EPC compared to control (678.7644.1 vs. 340.0629.1 CD34+/CD452 cells/16105
mononuclear cells, P,0.05) and their recruitment to the ischemic muscles (5.960.7 vs. 2.660.4 CD34+ cells/HPF, P,0.001) 3
days after the last injection.
Conclusions/Significance: Intramuscular injection of EPC-CM is as effective as cell transplantation for promoting tissue
revascularization and functional recovery. Owing to the technical and practical limitations of cell therapy, cell free
conditioned media may represent a potent alternative for therapeutic angiogenesis in ischemic cardiovascular diseases.
Citation: Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, et al. (2009) Novel Cell-Free Strategy for Therapeutic Angiogenesis: In Vitro Generated
Conditioned Medium Can Replace Progenitor Cell Transplantation. PLoS ONE 4(5): e5643. doi:10.1371/journal.pone.0005643
Editor: Joseph Najbauer, City of Hope Medical Center, United States of America
Received January 5, 2009; Accepted April 29, 2009; Published May 21, 2009
Copyright:  2009 Di Santo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This Study was supported in part by the Swiss National Science Foundation (Grant No. 3200B0-114100 to C.K), the Swiss Heart Foundation to C.K and
the University of Bern, Switzerland (Grant-in-aid to C.K). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vascmed.unibe@gmail.com
. These authors contributed equally to this work.
Introduction
Cell-based revascularization therapies have recently been tested
in clinical trials investigating the therapeutic benefits in patients
that suffer from ischemic cardiovascular diseases [1,2]. Most of
these studies used autologous cell transplantation given the
concern of immune-system reactions. Distinct progenitor and
stem cell lines have been described for their outstanding potential
to promote tissue revascularization and functional recovery of the
affected organ. Thus, a variety of progenitor and stem cell types,
isolated from bone marrow and peripheral blood, have been used
in patients with myocardial infarction, heart failure and peripheral
vascular disease [3]. However, technical and practical limitations
due to the invasive methods of harvest and low abundance may
hinder the adoption of progenitor cells in clinical applications.
Two predominant mechanisms by which progenitor cells like
endothelial progenitor cells (EPC) contribute to postnatal neovas-
cularization have been identified so far [4–7]. In vivo animal studies
demonstrated that EPC contribute to vessel formation by
differentiation into mature endothelial cells and incorporation
into the growing vessel wall [8,9]. However, this mechanism seems
to play only a marginal role [10–13]. Secondly, circulating EPC
isolated from peripheral blood have been shown to release a
number of proangiogenic factors [5,14]. As a matter of fact,
conditioned medium obtained from EPC cultures contains various
proangiogenic growth factors and may therefore support the
repair and re-endothelization of injured vessels and thus the
regeneration of ischemic tissues [15–17]. We hypothesized that the
regenerative potential of paracrine factors secreted by EPC may
represent a potent alternative to progenitor cell therapy.
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Results
Secretion of growth factors by EPC is increased by
hypoxia
We have measured the release of different growth factors to
determine to what extent hypoxia enhances the paracrine activity
of EPC. Indeed, hypoxia (1.5% O2) induced a significant increase
in accumulation of selected factors like Angiogenin, HGF, IL-8,
PDGF-BB, SDF-1 and VEGF-A in the EPC conditioned media
compared to normoxia (P,0.05; Table 1). This effect was due to
an augmented secretion since the overall EPC number was not
significantly influenced by the oxygen level during culture (data
not shown). Therefore, the growth factor enriched EPC-CM from
hypoxic cultures was used for subsequent experiments.
EPC-CM enhances endothelial cell-viability in vitro
The capacity of EPC-CM to support the viability of nutrient
depleted HUVEC was assessed by an assay for survival and for
apoptosis. Incubation of EPC-CM resulted in a 45.467.0%
increase of viable cells compared to control medium (P,0.001;
Figure 1A). In contrast, the caspase 23/7 activity was reduced to
52.362.3% in HUVEC incubated with EPC-CM compared to
control medium (P,0.001; Figure 1B).
EPC-CM increases vascular sprouting
The ex vivo aortic ring assay is commonly used to study the
outgrowth of endothelial and surrounding perivascular cells and
their organization in tubular, vessel-like structures. EPC-CM
showed a substantially higher angiogenic potential to stimulate
vessel outgrowth from the aortic ring in comparison to control
medium. This was evidenced by a significantly wider (50.6969.41
vs. 140.9067.41 mm, P,0.001) and clearly denser network of
vascular sprouts arising from the aorta (Figure 2).
EPC-CM and EPC transplantation both improve hindlimb
perfusion and muscle function
The animal experimental design is illustrated in Figure 3. In the
animals receiving control medium, blood flow remained constant
throughout the study around 50% of that measured in the non-
ischemic limb (53.562.4% at five weeks after treatment). In
contrast, the rats treated with EPC-CM or EPC showed a
significant improvement in blood flow already by one week after
the last injection (P,0.01). Subsequently, blood flow increased
gradually to a level of 81.262.9% (EPC-CM) and 83.763.0%
(EPC) after five weeks (P =n.s. between the two treated groups;
Figure 4A, B).
The improved flow recovery in the ischemic hindlimb was
associated with a clear restoration of muscle function. Rats treated
with control media had severely limited muscle activity with a
stroke ratio decreasing from 0.8360.02 to 0.6760.02 within the
first two minutes of swimming (P,0.05). The exercise perfor-
mance deteriorated further until they were unable to swim in the
third minute due to obvious exhaustion (near-drowning). In
comparison, EPC-CM and EPC treated animals had a signifi-
cantly better muscle function as evidenced by a stable hindlimb
stroke ratio throughout the exercise (EPC-CM, 0–1 min:
0.8960.02; 1–2 min: 0.8560.02; 2–3 min: 0.8360.03 and EPC,
0–1 min: 0.8660.01; 1–2 min: 0.8260.04, 2–3 min: 0.8160.08).
The group of non-operated, healthy control animals demonstrated
a uniform one to one stroke ratio during the entire exercise
protocol (Figure 5A).
Consistent with functional improvement, viability of the
ischemic muscle in control medium treated animals was down to
61.464.3% of the healthy hindlimb value (Figure 5B), while in the
EPC-CM and EPC group the viability was restored to 95.362.2%
and 95.964.0% of healthy muscle (both P,0.05).
Figure 1. Pro-survival properties of EPC-CM. Serum starved HUVEC were incubated in EPC-CM or control medium for 24 hrs and analyzed for
cell survival and extent of apoptosis. (A) The number of viable cells was assessed by CyQuantH NF and expressed relative to control. (B) Apoptosis
was measured by the level of caspase 23/7 activity by Apo-ONEH and expressed relative to control. *, P,0.001.
doi:10.1371/journal.pone.0005643.g001
Table 1. Concentration of selected angiogenic growth
factors in EPC-CM.
Cytokine/Growth factor Concentration (pg/ml)
Hypoxia Normoxia
IL-8/CXCL8 29090.7612279.4 2282.16406.3
SDF-1/CXCL12 6059.96654.6 3179.96488.0
HGF 539.56141.7 343.4674.8
Angiogenin 144.6668.2 72.5615.8
PDGF-BB 111.6627.02 19.962.2
VEGF-A 25.564.8 11.465.2
Selected cytokine levels were measured in the conditioned media from culture
expanded EPC incubated in hypoxic or normoxic condition for 72 hours.
doi:10.1371/journal.pone.0005643.t001
Paracrine Effect of EPC
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EPC-CM and EPC transplantation equally induce
neovascularization and vascular maturation
Five weeks after treatment, the number of capillaries in
hindlimbs treated with control media was 0.9260.02 per muscle
fiber which reflects a more than 40% reduction in capillary density
in comparison to non-operated, healthy tissue (1.9060.02,
P,0.05). However, treatment with EPC-CM (1.6260.03,
P,0.05) and EPC (1.6860.05, P,0.05) induced significant
increase in capillary density returning the capillary number to
almost 90% of that found in a normal, healthy hindlimb
(Figure 6A, B). No evidence of focally enhanced vascularization
was detected, as the ratio of capillary density/muscle fiber
Figure 2. Angiogenic potential of EPC-CM. (A) Representative pictures of vascular outgrowth from 1 mm rat aortic ring embedded in growth
factor reduced-MatrigelTM and incubated with EPC-CM or control medium. Incubation with EPC-CM enhanced the formation of capillary outgrowth
compared to control medium. (B) Quantitative analysis of sprout length induced by incubation with control medium and EPC-CM. *, P,0.001.
doi:10.1371/journal.pone.0005643.g002
Figure 3. Design of in vivo experiments. Two in vivo experimental settings were designed to address the effect of the treatment modalities on tissue
regeneration and neovascularization (Exp. Set 1) as well as progenitor cells mobilization and recruitment (Exp. Set 2). In both settings, rats were treated
by 3 separate intramuscular injections within 7 days (iDAY1- iDAY7), 4 weeks after inducing ischemia as indicated by the white arrowheads (=). Black
arrowheads (.) indicate blood flow measurements by Laser-Doppler of the hindlimb. T indicates tissue harvest and immunohistochemistry analysis.
doi:10.1371/journal.pone.0005643.g003
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obtained from the gastrocnemius muscle at three different
anatomic levels showed a relatively uniform and widespread
vascularization (from proximal to distal: 1.6760.06, 1.6460.04,
1.6260.04, P= n.s.).
Furthermore, the number of NG2+ pericytes per capillary was
significantly higher in animals treated with EPC-CM (0.2560.02)
or EPC (0.2460.01) as compared to control medium treated rats
(0.1860.01, P,0.05; Figure 6C, D). In parallel, the number of
vessels coated by smooth muscle cells was also significantly higher
in animals treated with EPC-CM or EPC (8.660.3/HPF and
8.160.4/HPF) as compared to controls (4.960.3/HPF, P,0.05,
Figure 7).
EPC-CM transplantation stimulates mobilization and
recruitment of bone marrow-derived EPC to the ischemic
hindlimbs
Three days after the last injection, the number of CD34+/
CD452 progenitor cells/16105 mononuclear cells (MNC) [18]
was significantly elevated in the bone marrow (678.7644.1 vs.
340.0629.1, P,0.05, Figure 8A–C) and the peripheral blood
(54.7610.2 vs. 25.761.8, P,0.05, Figure 8D–F) of animals
treated with EPC-CM as compared to control media. Concom-
itantly, the number of CD34+ cells within the ischemic muscle
tissue of EPC-CM treated limbs were significantly higher than in
control media treated (5.960.7/HPF vs. 2.660.4/HPF in
Figure 4. EPC-CM and EPC transplantation improve blood perfusion in the ischemic hindlimb. (A) Representative images of hindlimb
blood flow measured by laser Doppler immediately after intramuscular injection of EPC-CM, EPC or control medium (iDAY1, 4 weeks after occlusion
of the femoral artery) and the end of the experiment (5 weeks after treatment, iDAY35). (B) Quantitative analysis of blood flow expressed as perfusion
ratio of the ischemic to the contralateral (non-operated) hindlimb over the observation period (iDAY1: day of EPC-CM or EPC injection; iDAY7; iDAY14;
iDAY21; iDAY28 and iDAY35: 1, 2, 3, 4 and 5 weeks after injection, respectively). *, EPC-CM vs. Control, P,0.01; {, EPC vs. Control, P,0.01.
doi:10.1371/journal.pone.0005643.g004
Figure 5. Effect of EPC-CM and EPC transplantation on ischemic muscle function and activity. (A) Muscle function was tested by
swimming exercise and expressed as the ratio of ischemic to healthy hindlimb stroke numbers in animals treated with EPC-CM, EPC, control medium
or non-operated animals. Swimming activity was monitored for 3 minutes at 1 minute intervals. Rats treated with control medium were not able to
complete the exercise due to obvious exhaustion with drowning. *, EPC-CM vs. Control, P,0.05; {, EPC vs. Control, P,0.05; { Non-operated vs. EPC-
CM and EPC, P,0.05. (B)Muscle mitochondrial activity in animals treated with EPC-CM, EPC or control medium was assessed by MTT reduction in the
healthy and ischemic hindlimbs. The activity index is indicated as the ratio ischemic to healthy MTT values per gram of dry tissue. *, P,0.05.
doi:10.1371/journal.pone.0005643.g005
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gasctrocnemius, P,0.001, Figure 9A, B). Interestingly, numbers of
CD34+ cells were similar in muscles from different anatomic
regions (5.360.4/HPF vs. 2.260.3/HPF in adductor muscle,
P,0.001), suggesting a widespread recruitment of progenitor cells
rather than a localized migration (Figure 9C). Analysis of tissue
sections from later time points (iDAY 35) showed a decline of
CD34+ cells to levels similar to control media treated animals
(Figure 9D–F). These results indicate a temporary but potent
systemic effect of EPC-CM on mobilization and homing of
progenitor cells to the ischemic muscle.
Figure 6. Effect of EPC-CM and EPC transplantation on ischemic muscle neovascularization. (A) Representative images of healthy (non-
operated) and ischemic hindlimb muscle of animals treated with EPC-CM, EPC or control medium stained with BS-1 lectin (FITC) to localize capillaries.
(B) Quantitative analysis of capillary density expressed by the number of capillaries per muscle fiber. *, P,0.05. (C) NG2+ pericytes (white arrows)
were identified (red fluorescence) by being adjacent to endothelial cells stained for von Willebrand Factor (green fluorescence). (D) Quantitative
analysis of NG2+ cells per capillary in healthy and ischemic hindlimbs treated with EPC-CM, EPC and control medium. *, P,0.05.
doi:10.1371/journal.pone.0005643.g006
Paracrine Effect of EPC
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Discussion
In the present study we demonstrate that paracrine factors
released by in vitro expanded EPC have a potent therapeutic
capacity in a rat model of hindlimb ischemia. We present
convincing evidence that treatment with EPC-CM leads to a
substantial increase in blood flow in the presence of augmented
neovascularization, vascular maturation and muscle function in
the ischemic hindlimb. Most importantly, the observed regener-
ative potential after EPC-CM was equivalent to that achieved by
EPC transplantation.
Emerging evidence suggests that paracrine signals from stem
and progenitor cells are fundamental players in various processes
of tissue repair [14,15,19,20] integrating the mechanisms relying
on cell differentiation and engraftment. Preclinical studies have
described that EPC secretion of factors involved in the regulation
of stem cell recruitment and in vascular growth and remodeling
(such as SDF-1, VEGF, HGF and MMP-9) [5,17] support the
function of mature endothelial cells in vitro and tissue regeneration
in a variety of animal models [21,22]. However, despite the fact
that the regenerative capacity of EPC-secreted factors is
recognized [23] the spectrum of paracrine effectors and their
mechanisms of action remain largely unexplored. Recently the
characterization of multifaceted nature of the EPC secretome has
been addressed [16] but further investigations are needed to clarify
the activation and the interactions of downstream signals.
Although the aim of this work was not the identification of the
molecular effectors responsible for the angiogenic properties of
EPC-CM, we have confirmed that EPC release key angiogenic
molecules such as Angiogenin, HGF, IL-8, PDGF, SDF-1 and
VEGF in culture. Consistent with previous studies reporting the
stimulatory activity of hypoxia on differentiated endothelial cells
and EPC, we found an increased secretory activity under hypoxic
conditions [22,24]. Accordingly, the blend of growth factors
contained in the EPC-CM disclosed a strong capacity to sustain
fundamental biological functions of mature endothelial cells such
as endothelial viability and sprouting. The pro-survival activity of
EPC-CM is of utmost relevance in the patho-physiological
scenario of chronic muscle tissue ischemia where viability of
resident endothelial cells is compromised by the reduced oxygen
and nutrient supply [25].
A better understanding of the mechanisms by which cytokines
support the functions of resident cells and circulating bone
marrow-derived cell populations has led to the development of a
number of therapeutic angiogenesis strategies. These include the
direct delivery of a variety of recombinant cytokines [26–28] or the
gene encoding the desired angiogenic protein [29–32]. However,
clinical trials based on the administration of a single factor have
shown contrasting results [31,33,34] probably reflecting the fact
that the synergic activity of different growth factors is needed to
induce formation of stable vascular networks [35,36]. In contrast
to findings after VEGF monotherapy, which promotes intense
endothelial sprouting, but results in the development of leaky and
disorganized conduits [37], EPC-CM induced the formation of a
persistent capillary network as clearly evidenced by long-lasting
enhanced density of capillaries and mature vessels as detected five
weeks after injection. From this one can speculate that the
complex process of revascularization in ischemic tissue is improved
by the number of soluble factors present in the EPC-CM, which
are presumably able to target simultaneously multiple cell types.
The findings reported here potentially have important implica-
tions for the development of novel therapeutic strategies. Most
importantly, our data suggest a strategy free from the limitations
and problems observed with cell transplantation [38]. It has been
described that age and other cardiovascular risk factors reduce the
availability and function of EPC, thus limiting their therapeutic
applicability in affected patients [39–41]. Furthermore, the relative
scarcity of circulating EPC and their limited proliferative potential
prevent the possibility of expanding these cells in sufficient
numbers for some therapeutic applications. Therefore, the use of
heterologous cells seems to be the only available option to provide
patients suffering from cardiovascular disease with a cell-based
therapy. However, immunotolerance concerns and technical as
well as practical difficulties may hinder this type of treatment. In
contrast, a cell-free medium such as EPC-CM significantly reduces
the risk of adverse immunological reactions, simplifies the process
Figure 7. Effect of EPC-CM and EPC transplantation on vascular maturation. (A) Representative images of healthy and ischemic hindlimb
muscle of animals treated with EPC-CM, EPC or control medium stained with a-smooth muscle actin (a-SMA) to evidence vascular maturation (red
staining, white arrows). (B) Quantitative analysis of a-SMA+ vessels per high power field (HPF). *, P,0.05.
doi:10.1371/journal.pone.0005643.g007
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Figure 8. EPC-CM stimulates the mobilization of bone marrow-derived EPC. Representative FACS analysis charts of CD34+/CD452 cells
isolated from bone marrow (A and B) and peripheral blood (D and E) of EPC-CM and control media treated animals 3 days after the last
intramuscular injection. Quantitative analyses show significantly increased numbers of CD34+/CD452 progenitor cells in the BM (C), and the
peripheral blood (F) of EPC-CM treated animals. *, P,0.05.
doi:10.1371/journal.pone.0005643.g008
Paracrine Effect of EPC
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of production and thus increases the availability of the therapy. In
the present study we have used hypoxic culture conditions to
achieve maximum concentrations of growth factors and chemo-
kines in the conditioned medium of EPC [42]. Since the aim of
our research was to investigate an alternative therapeutic option to
current pre-clinical and clinical EPC transplantation protocols
which apply normoxic culture conditions, we have compared the
regenerative potential of hypoxic EPC-CM to normoxic EPC
cultures. It is of note that the amount of cells required to generate
a therapeutic dose of EPC-CM is significantly lower in comparison
to the number of EPC needed for transplantation. More precisely,
the number of EPC injected was 8-fold higher than the number of
Figure 9. EPC-CM promotes progenitor cells homing to the ischemic tissue. Representative fluoresence pictures of CD34+ immunostaining
in ischemic hindlimb tissue 3 days (left panel, iDAY10) and 4 weeks after treatment (right panel, iDAY35). The number of CD34+ cells on iDAY10 was
significantly higher in EPC-CM treated limbs (A) as compared to control treated animals (B) with no evidence for focal recruitment, as CD34+ cells
were found to similar extent in different anatomic regions (C). In comparison, 4 weeks after treatment (iDAY35), tissue sections from show decreased
numbers of CD34+ cells in EPC-CM treated limbs (D) equivalent to numbers found in control (E). Quantitative analysis is depicted reflects the
temporary recruitment of CD34+ cells to the ischemic limbs in EPC-CM treated animals (F). *, P,0.001.
doi:10.1371/journal.pone.0005643.g009
Paracrine Effect of EPC
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cells required to generate the volume of EPC-CM needed to
achieve the same therapeutic benefit. We speculate that a
considerable number of EPC undergo cell death during and after
transplantation. Additionally, the unfavorable microenvironment
present in the ischemic tissue might impair the effectiveness of cell
transplantation. In contrast, the administration of a mixture of
physiologically relevant cytokines and growth factors as by EPC-
CM injection, might induce a permissive milieu for differentiated
as well as progenitor cells of the host and thus stimulate the
endogenous repair system [43–45]. The prolonged re-vasculari-
zation of the ischemic tissue induced by EPC-CM treatment is
intriguing given the short half-life of growth factors. In fact, rapid
inactivation and degradation are major limitations of the
therapeutic approach using intravenous or intramuscular protein
applications [46]. The presented data therefore suggest that in our
experimental setting the integrity of the proteins in EPC-CM is
preserved resulting in a sustained level and activity of growth
factors in the tissue with a long-lasting angiogenic effect.VEGF
and SDF-1 may be key factors in amplifying the angiogenic signals
of EPC-CM as both have be shown to recruit and entrap pro-
angiogenic BM-derived cells in the ischemic tissue [47,48]. Indeed,
our data provide evidence that intramuscular injection of EPC-
CM effectively enhanced the number of EPC in the BM,
promoted mobilization into the peripheral blood and their homing
to the ischemic limbs. In accordance with previous publications,
this effect appears to be temporally limited [49]. Interestingly, this
recruitment as well as the induction of neovascularization do not
show a focal pattern but appear rather equally distributed
throughout the ischemic muscle.
Taken together, our observations support the concept that EPC-
CM has the potential to replace cell transplantation. Moreover,
this study provides a reference for future investigations which will
improve our understanding of the regenerative properties of EPC.
In particular, knowledge about the differences in healing capacity
between EPC-CM obtained from healthy donors and patients with
cardiovascular risk factors in combination with the elucidation of
their respective secretomes will give the opportunity to define the
paracrine functions of EPC in health and disease. These advances
will then serve to set up an effective tool to support the defective
paracrine processes in the ischemic tissues. It is, therefore,
reasonable to imagine that the development of a synthetic
preparation which mimics physiological EPC-CM could provide
clinicians with a readily available product of standardized quantity
and quality.
In conclusion, we have demonstrated in the present study that
the constellation of soluble factors secreted by in vitro expanded
EPC is able to support revascularization of hindlimb ischemic
tissue. These data strongly suggest that interventions based on
EPC paracrine factors might effectively replace cell transplanta-
tion. Future studies designed to identify these factors and the
activation of the respective downstream cellular targets might
ultimately provide a more effective and practical therapeutic
strategy for the treatment of ischemic diseases.
Materials and Methods
Cell and conditioned medium preparation
Human peripheral venous blood samples were obtained from
healthy, young volunteers (n = 7, age range: 24–38 years) with
informed consent. The MNC population was isolated by gradient
centrifugation and cultured for 7 days in complete endothelial cell
growth medium (EGM-2-MV, Lonza, Switzerland) containing 5%
fetal bovine serum (FBS) to obtain EPC in accordance with
previously published method [11]. To produce human EPC
conditioned medium (EPC-CM), EPC were cultured for 72 hours
under hypoxic conditions (1.5% O2, 5% CO2, 93.5% N2) in
growth factor-free endothelial cell basal medium-2 (EBM-2,
Lonza, Switzerland) with 1% FBS. The conditioned medium
was then collected and centrifuged to harvest a cell-free solution.
EBM-2 containing 1% FBS without supplements served as control
medium. Human umbilical vein Endothelial Cells (HUVEC) were
isolated from umbilical cords and cultured using a standard
protocol [50]. All protocols received full approval from the
Cantonal and the Institutional Ethics Review Board and a signed
informed consent was obtained from all participants.
ELISA and multiplex assay
The concentration of Angiogenin, Hepatocyte Growth Factor
(HGF), Interleukin-8 (IL-8), Platelet Derived Growth Factor B
(PDGF-BB), Stromal Cell-Derived Factor -1 (SDF-1) and Vascular
Endothelial Growth Factor A (VEGF-A) was assessed in EPC
culture supernatants generated under normoxic or hypoxic
conditions. Angiogenin levels were determined by ELISA (RayBio-
tech, Norcross GA, USA) whereas the concentration of the other
cytokines was done using a multiplex assay (Bioplex, Bio-Rad,
Switzerland) following the manufacturer’s instructions. All mea-
surements were performed in duplicates from five different donors.
Cell survival assay
HUVEC were seeded into 96-well plates coated with 1% gelatin
and starved in EBM-2 containing 1% FBS for 24 hours. The cells
were then exposed to EPC-CM or control medium. After 24 hours
the number of viable cells was assessed by use of the CyQuantH
NF kit (Molecular Probes, Switzerland). The level of apoptosis was
determined measuring the caspase 23 and 27 activity (Apo-
ONEH Homogeneous Caspase 23/7 Assay, Promega AG,
Switzerland). All experiments were performed in quadruplicates
with EPC-CM generated from five different EPC donors.
In vitro angiogenesis assay
Aortas isolated from nude rats were cut into 1 mm thick rings and
placed individually in a 24-well plate coated with growth factor-
reduced MatrigelTM (Becton Dickinson, Germany) [51] and
incubated with EPC-CM or control medium. The experiment
was performed in quadruplicates for each culture condition. After 5
days of culture, sprout length was calculated digitally using ImageJ.
In vivo experimental design
The in vivo experimental design of the study is schematically
depicted in Figure 3. Experimental set 1 was designed to
investigate the long term effect of the different treatment strategies
on hindlimb perfusion and function. Aim of Experimental Set 2
was to evaluate the stimulation and recruitment of host cells
involved in the endogenous repair system in response to EPC-CM
treatment.
In vivo angiogenesis model
Chronic hindlimb ischemia was induced by unilateral excision
of an arterial segment extending from the external iliac to the
femoral vessels (artery and vein) in male athymic nude rats (NIH-
Foxn1rnu, Charles River Laboratory Inc, Sulzfeld, Germany)
during 0.2% isoflurane anesthesia. Buprenorphinum (TemgesicH,
0.1 mg/kg, Essex Chemie, Switzerland) was injected subcutane-
ously at the end of the procedure. Rats were then randomly
assigned to 3 treatment groups (n = 8 in each group) for 3 serial
intramuscular injections of EPC-CM, EPC or control medium
within 7 days (Figure 3). Injections were performed four weeks
Paracrine Effect of EPC
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following arterial occlusion (iDAY1). Each time a total volume of
250 ml EPC-CM or control medium, or 16106 EPC were injected
at 5 sites into the ischemic hindlimb distal to the arterial occlusion
site. Three ventral injections were placed in the upper limb in
proximity to the adductor and semimembranosus muscles. The
remaining 2 injections were administered to the ventral lower limb
involving the gastrocnemius and flexor digitorum muscles. In
order to achieve maximal experimental uniformity, transplanted
EPC and EPC-CM were derived from the same donors and used
in parallel experiments. All procedures were approved by the
Cantonal Ethics Review Board and conducted in accordance with
the institutional policies for animal experiments.
Laser Doppler blood perfusion imaging
Blood flow in the ischemic and healthy lower hindlimbs was
measured weekly until iDAY 35 using a laser Doppler Imager
(Moor, Axminster, UK). The animals were placed on a heating
pad in order to maintain a constant body temperature during the
entire measurement. In each rat the values of two consecutive
measurements were averaged and the perfusion was expressed as
ratio of values for the ischemic to normal limb [11].
Assessment of hindlimb function
We adopted a forced swimming test to determine the functional
capacity of the ischemic hindlimb after treatment [52]. Animals
were placed in a water-filled tank (23uC) to swim. Active strokes
per minute of each limb were counted during 3 consecutive
periods (0–1 min, 1–2 min, and 2–3 min). Functional muscle
activity was calculated as the ratio of number of strokes/min of the
ischemic to the healthy hindlimb and compared to non-operated,
age-matched healthy rats (n = 5).
Assessment of muscular viability and
immunohistochemistry
All animals were euthanized by use of carbon dioxide five weeks
after treatment for analysis of mitochondrial activity and
immunohistochemistry. The mitochondrial activity, serving as a
surrogate marker of muscular viability, was assessed in the
hindlimb muscles by the MTT reduction test. Muscle viability
was calculated as the ratio of extracted MTT absorbance values
per gram of dry tissue of the ischemic and the healthy contralateral
limb [53]. The gastrocnemius muscle of the hindlimb was fixed in
4% formaldehyde for 24 hours and embedded in paraffin. Ten
mm thick sections were stained with lectin from Bandeiraea
simplicifolia (BS-1, Sigma-Aldrich, Germany) or with von Will-
ebrand factor (vWF; AB7356, Chemicon, USA) in order to
determine capillary density in the muscle tissue. Vascular mural
cells were identified as cells immunoreactive for NG2 (N8912,
Sigma-Aldrich, Germany) adjacent to endothelial cells stained
with vWF. A mouse monoclonal antibody against rat a-smooth
muscle actin (a-SMA, Sigma-Aldrich, Germany) and the LSABTM
- alkaline phosphatase kit (Dako, USA) were used to localize
vascular maturation [54]. The number of capillaries, NG2+
pericytes and smooth muscle cell-covered vessels was counted in 5
random high power fields (HPF) by use of ImageJ software.
Capillary density was expressed as the ratio of capillary numbers
per muscle fiber. NG2+ pericyte density was expressed as the ratio
of cell numbers per capillary. A total of 10 sections from 3 different
muscle levels were obtained per animal and analyzed by a blinded
investigator.
Progenitor cells mobilization
To investigate whether the effect of intramuscular applied EPC-
CM on tissue regeneration and neovascularization involves the
endogenous repair system of bone marrow-derived progenitor
cells, we performed experiments according to Experimental Set 2
(Figure 3) to evaluate mobilization, recruitment and homing of
progenitor cells [18]. The number of CD34+/CD452 progenitor
cells was measured in the bone marrow and the peripheral blood
of EPC-CM and control media treated animals (n = 5) using flow
cytometry 3 days after the last treatment. Immediately following
isolation, MNC from BM and PB were processed for FACS
analysis. The expression of surface markers CD34 (Santa Cruz,
USA) and CD45 (Cedarlane Laboratories, Canada) were
measured in a LSR II flow cytometer (Becton Dickinson, USA)
using the Cell Quest software (Becton Dickinson, USA).
Immunofluorescence staining was used to determine the number
of CD34+ cells in both adductor and gastrocnemius muscles from
ischemic hindlimbs. To compare the recruitment of CD34+ cells at
different time points, immunofluorescence staining for CD34+ cells
was also performed in tissue sections from gastrocnemius muscles
harvested at iDAY35.
Statistical analysis
Data are reported as means6SEM unless otherwise stated.
Proportions were compared by use of Pearson`s X2-Test and
Fisher`s exact test, respectively, applying the Bonferroni correction
for repetitive testing. Kruskal-Wallis test and post-hoc comparison
with Scheffe’s test were used to compare means of continuous
variables amongst the different study groups. Statistical signifi-
cance was inferred at a 2-sided value of P,0.05. Statistics were
carried out using SPSS software package (version 16.0; SPSS Inc,
Chicago, IL).
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript
as written.
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